Replies to post #20183 on MedSmart Group Inc (MSGP)

[SPARK]

Great post Sterling ..thanks~

[shemp]

outstanding DD stervc!!!

(member mark for you pal!)

[Fatboy46]

Good to see you around stervc, Solid DD as per usual.
Thanks

[MarsBodo]

Thanx! Marked!

[WakingBake]

What an amazing DD post!! Sticky please!

[SPARK]

I agree~ The submissions have taken place and more are continuing which leads me to think that a major announcement with a major pharma company is near at hand to be announced.

[purefreewater]

I hope that everyone understands the magnitude of

releasing 6 announcements via just ONE Press Release !!!!!!!



think about it ........ and keep thinking about it !!!!!!!






( not getting ready to (dump &/or) dilute while announcing stuff

and a lot more good news coming soon ....... IMHO )


thanks for that post Stervc !

[familyof5]

"The submissions have taken place and more are continuing which leads me to think that a major announcement with a major pharma company is near at hand to be announced."


stervc I read your post and most notable the above statement from that post.It has gotten me so excited that I now cannot sleep LOL.Good post keep em coming my friend!

[SPARK]

Absolutely!! - To have one of your products submitted for FDA approval with the doctor who is the founder of Listerine and Neosporin should be given huge attention for where this is going in my opinion.

[balamidas]

Sterling,SSWC is way Bigger than i thought !!!Unreal potential here!!!

thank U for those great DD

To have their products submitted for FDA approval with the doctor who is the founder of Listerine and Neosporin!!!

this is HUGE !!!!

thank U for your hard work

regards

[balamidas]

Dr Alain Martin is the CEO of North Cell Pharmaceutical


http://www.northcellpharma.com/

http://www.northcellpharma.com/aboutus2.html

North Cell Pharmaceutical has developed a technology platform of patented ingredients (Skin Resuscitation Factor™ SRF™) that can down regulate inflammation (eliminate the destruction of nitric oxide to peroxynitrite), to enhance healing or to up regulate nitric oxide that can be used by the human body to kill bacterial, viral, and fungal infections and tumors. SRF™ can be used independently to create new products or can be added to existing products to enhance efficacy and to generate new product claims.

North Cell and GlaxoSmithKline Sign Agreement
North Cell Pharmaceutical, Inc. and GlaxoSmithKline Consumer Healthcare have entered into an Option and Development Agreement regarding North Cell’s Skin Resuscitation FactorTM (SRFTM ) technology for use in certain applications. . .

North Cell Granted New Patent On
Anti-Cancer Compound
Immunostimulator anti-cancer compounds and methods for their use in the treatment of cancer

[balamidas]

North Cell Pharmaceutical, Inc.&SSWC deal is close now with a seven figure payment for SSWC $$$

if we put events in a Chronological way

from june 21 PR :


http://finance.yahoo.com/news/SpeechSwitch-Inc-PINKSHEETS-iw-898046730.html?x=0&.v=1



In June 2009 the company obtained all rights to the GlynnTech, Inc. cancer drug delivery system, at cost. This includes one issued patent (US No. 7,637,889 B2), one pending application, three years of development work, a prototype, numerous CAD drawings of various embodiments, risk analysis and development pre-FDA filing history. Ken had three meetings with a major pharma company who expressed serious interest and has indicated that a contract will likely be offered for acquisition of the intellectual property after FDA filings have been made, but before FDA approval. If successful, a seven figure payment would be expected


and then come the the june 28 PR :

http://finance.yahoo.com/news/SpeechSwitch-Inc-USOTC-SSWC-iw-318914569.html?x=0&.v=1

"The third invention is a collaboration between Dr. Alain Martin and Ken Glynn, as co inventors, utilizing the same wound care technology, but including Dr. Martin's proprietary antioxidant, anti-inflammatory cell growth accelerants. Dr. Martin is the inventor of Neosporin and other successful products, and is currently the CEO of North Cell Pharmaceutical, Inc. SpeechSwitch and North Cell will be equal partners in this alliance."


and then come the 6 july PR :

http://finance.yahoo.com/news/SpeechSwitch-Inc-USOTC-SSWC-iw-3440709283.html?x=0&.v=1

Ken also announced that the first patent application on biodegradable bandages will be filed before July 12, 2010, that the second will be filed by July 30, 2010 and that the joint application with Dr. Alain Martin, (the inventor of Neosporin and other commercially successful products) will be filed shortly thereafter


and here come July 27 PR the confirmation of june 21 PR for the upcoming deal:

http://finance.yahoo.com/news/SpeechSwitch-Inc-USOTC-SSWC-iw-3506349087.html?x=0&.v=1

The second biodegradable disposable bandages patent application
will be filed August 1st as forecast, and the third application, with co-inventor Dr. Alain Martin (of Listerine and Neosporin fame) is in progress.


key words from june 21

"a contract will likely be offered for acquisition of the intellectual property after FDA filings have been made, but before FDA approval and a seven figure payment would be expected "

summary of events

FDA filings are almost DONE :)Deal is on the way for SSWC
with a seven figure payment $$$$$$


more about

Dr Alain Martin (the founder of Listerine and Neosporin) is the CEO of North Cell Pharmaceutical


http://www.northcellpharma.com/

http://www.northcellpharma.com/aboutus2.html

North Cell Pharmaceutical has developed a technology platform of patented ingredients (Skin Resuscitation Factor™ SRF™) that can down regulate inflammation (eliminate the destruction of nitric oxide to peroxynitrite), to enhance healing or to up regulate nitric oxide that can be used by the human body to kill bacterial, viral, and fungal infections and tumors. SRF™ can be used independently to create new products or can be added to existing products to enhance efficacy and to generate new product claims.

North Cell and GlaxoSmithKline Sign Agreement

North Cell Pharmaceutical, Inc. and GlaxoSmithKline Consumer Healthcare have entered into an Option and Development Agreement regarding North Cell’s Skin Resuscitation FactorTM (SRFTM ) technology for use in certain applications. The further details of the Agreement remain confidential.

SRFTM is a patent applied for technology that can be added to products in order to enhance product performance and the healing of any lesions or wounds associated with the underlying skin condition being treated.

[Kooka_Duke]

" Brilliant DD Bro "

[trade06]

sterling,

first, i hold a high degree of respect of your integrity and credibility. i also am a $kat holder too since december 2009.

regarding swcc, the ibox lacks share structure; (ie. O/S, A/S, RESTRICTED, FLOAT)

I am interested to optain this information to facilitate my SWCC d.d.


kind regards

[playerguy]

Sterling, what do you think the potential impact of the 6 billion restricted shares. I had heard that when the CE is removed the previous CEO could sell his restricted shares but I don't know how many he has. I also do not know the period or conditions of the other restricted shares.

[I Like Bottom Fishing]

SpeechSwitch, Inc. (USOTC:SSWC) SEC Filings Begin.

Monday , September 27, 2010 13:00ET

http://www.knobias.com/story.htm?eid=3.1.14a72561c577abc33a327da6df0db9e56cef07896f9ecf219b3f3ef45297cf24

http://www.knobias.com/individual/public/quote.htm?ticker=SSWC

http://www.otcmarkets.com/stock/SSWC/financials

http://www.barchart.com/detailedquote/stocks/SSWC

FLEMINGTON, NJ -- (Marketwire) -- 09/27/10 -- Ken Glynn, President of SpeechSwitch, Inc. (PINKSHEETS: SSWC), reported today that the first of required SEC documents to bring the company current was submitted today for EDGAR review. The third quarter, 2008 Form 10-Q has been completed and submitted to Marketwire for conversion and filing with the U.S. Securities Exchange Commission. This filing will be completed by noon tomorrow. Additional filings will be made over the next two weeks. The annual report for 2008 (end of year10-K) will be submitted by the end of this week; First quarter, 2009 Form 10Q will be filed early next week. The company has made a stepped up effort to bring the company current as a pink sheet company as quickly as possible.

Information set forth in this press release contains various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Private Securities Litigation reform Act of 1995 (the "Act") provides certain "safe harbor" provisions for forward-looking statements. The reader is cautioned that such forward-looking statements are based on information available at the time and/or management's good faith belief with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed statements. Forward-looking statements speak only as of the date the statement was made. We assume no obligation to update forward-looking information to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information. Forward-looking statements are typically identified by the use of terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "should," "will," and similar words, although some forward-looking statements are expressed differently. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.

Contact:
Ken Glynn
908 788 0077


Source: SpeechSwitch, Inc.


Public Companies Associated with this story:
SSWC

Content provided by Market Wire Copyright © 2010
Content transmitted by Knobias.com Copyright © 2010 Visit Knobias.com

http://www.knobias.com/story.htm?eid=3.1.14a72561c577abc33a327da6df0db9e56cef07896f9ecf219b3f3ef45297cf24

http://www.knobias.com/individual/public/quote.htm?ticker=SSWC

http://www.otcmarkets.com/stock/SSWC/financials

http://www.barchart.com/detailedquote/stocks/SSWC

ABOUT | PARTNERS | ADVERTISING INFO | CONTACT US | COPYRIGHT | PRIVACY | LEGAL | DISCLAIMER
Copyright © 2010 Knobias.Com, LLC. All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Knobias.Com, LLC, nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Knobias.Com website(s), a user agrees not to redistribute the information found therein. Knobias.Com, LLC is not a registered broker-dealer and does not endorse or recommend any securities listed herein or any services of any brokerage company.